HONG KONG, Sept. 22, 2017 /PRNewswire/ -- China Cord Blood
Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services, today announced that the Company
will hold its 2017 annual general meeting of shareholders at its
Hong Kong office at 48/F, Bank of
China Tower, 1 Garden Road, Central, Hong
Kong, at 9:00 p.m. Hong Kong
Time on December 7, 2017
(8:00 a.m. U.S. Eastern Standard Time
on December 7, 2017).
Shareholders of record as of October 27,
2017 will be entitled to receive notice of and vote at the
annual general meeting. The Company filed its annual report on Form
20-F, including its audited financial statements for the fiscal
year ended March 31, 2017, with the
U.S. Securities and Exchange Commission (the "SEC") on July 25, 2017. CCBC's annual report on Form 20-F
can be accessed at the Investor Center section of the Company's
website at http://www.chinacordbloodcorp.com, as well as on the
SEC's website at http://www.sec.gov. Shareholders may request a
meeting notice, proxy statement and hard copy of the annual report
on Form 20-F free of charge by contacting
ir@chinacordbloodcorp.com.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple
licenses. Under current PRC government regulations, only one
licensed cord blood banking operator is permitted to operate in
each licensed region and no new licenses will be granted before
2020 in addition to the seven licenses authorized as of
today. China Cord Blood Corporation provides cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services. For more information, please
visit our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934. These
statements relate to future events or the Company's future
financial performance. The Company has attempted to identify
forward-looking statements by terminology including "anticipates",
"believes", "expects", "can", "continue", "could", "estimates",
"intends", "may", "plans", "potential", "predict", "should" or
"will" or the negative of these terms or other comparable
terminology. These statements are only predictions, uncertainties
and other factors may cause the Company's actual results, levels of
activity, performance or achievements to be materially different
from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking
statements. The information in this press release is not intended
to project future performance of the Company. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company does not guarantee future
results, levels of activity, performance or achievements. The
Company expectations are as of the date this press release is
issued, and the Company does not intend to update any of the
forward-looking statements after the date this press release is
issued to conform these statements to actual results, unless
required by law.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/china-cord-blood-corporation-to-hold-annual-general-meeting-in-hong-kong-on-december-7-2017-300520984.html
SOURCE China Cord Blood Corporation